Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 1;7(1):32-39.
doi: 10.18683/germs.2017.1106. eCollection 2017 Mar.

Consensus statement on the management of patients with HCV infection in Romania

Consensus Statement on HCV Infection in Romania Working Group
Collaborators
Review

Consensus statement on the management of patients with HCV infection in Romania

Consensus Statement on HCV Infection in Romania Working Group. Germs. .

Abstract

Background: HCV direct-acting antivirals (DAAs) have made treatment easier for both patients and healthcare practitioners, but have also brought new challenges in terms of patient management and monitoring prior to, during, and after treatment.

Methods: To sum up and unify the clinical experience of Romanian DAA prescribing physicians, we have organized a Consensus Meeting in November 2016 in Bucharest, Romania.

Consensus statement: The Consensus Meeting has provided expert answers to ten significant questions regarding HCV infection, namely: How do we diagnose patients with HCV infection? How do we stage liver disease in patients with HCV infection? How do we monitor patients with HCV infection prior to treatment? Which patients with HCV infection do we treat? When do we start treatment for HCV infection? What regimens do we use for treating HCV infection? How do we monitor patients with HCV infection during treatment? What adverse events should we expect during treatment of HCV infection and how do we prevent/manage them? How do we monitor patients with HCV infection after treatment? How do we expect the landscape of HCV to change in the following years?

Keywords: DAA; HCV; adverse events; monitoring; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: - Ioan Ancuța: none declared.- Victoria Aramă: speaker/principal investigator in HCV and HBV trials by AbbVie, BMS, Merck, Roche.- Manuela Arbune: none declared.- Petre Iacob Calistru: none declared.- Florin Alexandru Căruntu: none declared.- Emanoil Ceauşu: none declared.- Lucia Carmen Chiriac: none declared.- Felicia Constandiş: none declared.- Augustin Cupşa: none to declare.- Manuela Gabriela Curescu: speaker/principal investigator in HCV trials by AbbVie.- Carmen Mihaela Dorobăț: none declared.- Corina Itu Mureşan: none declared.- Voichița Elena Lăzureanu: speaker for AbbVie, Janssen, Merck.- Mihaela Lupşe: none to declare.- Egidia Miftode: speaker for AbbVie.- Sorin Rugină: principal investigator in HCV trials by: AbbVie, Janssen, Merck.- Oana Săndulescu: speaker and subinvestigator in HCV trials by AbbVie and Boehringer Ingelheim; subinvestigator in HCV trials by Merck.- Adrian Streinu-Cercel: received a grant from AbbVie and was speaker/principal investigator in HCV trials by: AbbVie, Boehringer Ingelheim, Janssen, Merck.- Anca Streinu-Cercel: speaker/subinvestigator in HCV trials by: AbbVie, Boehringer Ingelheim, Janssen, Merck.

References

    1. Streinu-Cercel A, Moțoi M, Neguț A, et al. Assessment of adherence to chronic viral hepatitis C treatment in Romania: an open, single center, prospective study. J Contemp Clin Pract. 2016;2:59–68.
    1. Sporea I, Gradinaru-Tascau O, Bota S, et al. How many measurements are needed for liver stiffness assessment by 2D-Shear Wave Elastography (2D-SWE) and which value should be used: the mean or median? Med Ultrason. 2013;15:268–72. - PubMed
    1. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest) and transient elastography (FibroScan) J Hepatol. 2014;60:706–14. - PubMed
    1. Munteanu M. Biomarker panels and regression of fibrosis in chronic viral hepatitis. GERMS. 2015;5:115. - PMC - PubMed
    1. Bachofner JA, Valli PV, Kroger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2016 - PubMed

LinkOut - more resources